IRAFU

IRAFU is a Japanese biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting the innate immune system. The company leverages advanced structure-based drug design (SBDD) and computational chemistry to identify potent inhibitors of key signaling proteins, such as IRAK4, which play a critical role in Toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) pathways. IRAFU aims to address significant unmet medical needs in autoimmune disorders, chronic inflammatory conditions, and certain types of oncology. By optimizing the pharmacological profiles of its lead candidates, the company seeks to develop next-generation treatments with improved efficacy and safety compared to existing therapies.